DNA GTx’s NRAS Test detects 11 clinically relevant variants located in exons 2, 3, and 4 of the NRAS gene. This precise molecular profiling aids oncologists in selecting effective therapies and managing disease progression in patients with melanoma and colorectal cancer.
Yes. A healthcare provider must request the test and help interpret the results to guide your treatment plan.
Let’s Decode the Future of Health — Together
Get in touch today — let’s start a conversation that could change lives
*All information is handled with strict confidentiality.
Find Answers Today
Early detection saves lives
*All information is handled with strict confidentiality.